Clinical Trial Update: Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating paclitaxel, estramustine phosphate, and thalidomide in metastatic androgen-independent prostate cancer (Phase 1/2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Estramustine phosphate (estramustine phosphate)
• PACLITAXEL (PACLITAXEL)
• Thalidomide (thalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED